Cargando…

Systematic optimization for production of the anti‐MRSA antibiotics WAP‐8294A in an engineered strain of Lysobacter enzymogenes

WAP‐8294A is a group of cyclic lipodepsipeptides and considered as the first‐in‐class new chemical entity with potent activity against methicillin‐resistant Staphylococcus aureus. One of the roadblocks in developing the WAP‐8294A antibiotics is the very low yield in Lysobacter. Here, we carried out...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xusheng, Li, Shanren, Yu, Lingjun, Miller, Amanda, Du, Liangcheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801147/
https://www.ncbi.nlm.nih.gov/pubmed/31520522
http://dx.doi.org/10.1111/1751-7915.13484
_version_ 1783460520791113728
author Chen, Xusheng
Li, Shanren
Yu, Lingjun
Miller, Amanda
Du, Liangcheng
author_facet Chen, Xusheng
Li, Shanren
Yu, Lingjun
Miller, Amanda
Du, Liangcheng
author_sort Chen, Xusheng
collection PubMed
description WAP‐8294A is a group of cyclic lipodepsipeptides and considered as the first‐in‐class new chemical entity with potent activity against methicillin‐resistant Staphylococcus aureus. One of the roadblocks in developing the WAP‐8294A antibiotics is the very low yield in Lysobacter. Here, we carried out a systematic investigation of the nutritional and environmental conditions in an engineered L. enzymogenes strain for the optimal production of WAP‐8294A. We developed an activity‐based simple method for quick screening of various factors, which enabled us to optimize the culture conditions. With the method, we were able to improve the WAP‐8294A yield by 10‐fold in small‐scale cultures and approximately 15‐fold in scale‐up fermentation. Additionally, we found the ratio of WAP‐8294A2 to WAP‐8294A1 in the strains could be manipulated through medium optimization. The development of a practical method for yield improvement in Lysobacter will facilitate the ongoing basic research and clinical studies to develop WAP‐8294A into true therapeutics.
format Online
Article
Text
id pubmed-6801147
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68011472019-10-22 Systematic optimization for production of the anti‐MRSA antibiotics WAP‐8294A in an engineered strain of Lysobacter enzymogenes Chen, Xusheng Li, Shanren Yu, Lingjun Miller, Amanda Du, Liangcheng Microb Biotechnol Research Articles WAP‐8294A is a group of cyclic lipodepsipeptides and considered as the first‐in‐class new chemical entity with potent activity against methicillin‐resistant Staphylococcus aureus. One of the roadblocks in developing the WAP‐8294A antibiotics is the very low yield in Lysobacter. Here, we carried out a systematic investigation of the nutritional and environmental conditions in an engineered L. enzymogenes strain for the optimal production of WAP‐8294A. We developed an activity‐based simple method for quick screening of various factors, which enabled us to optimize the culture conditions. With the method, we were able to improve the WAP‐8294A yield by 10‐fold in small‐scale cultures and approximately 15‐fold in scale‐up fermentation. Additionally, we found the ratio of WAP‐8294A2 to WAP‐8294A1 in the strains could be manipulated through medium optimization. The development of a practical method for yield improvement in Lysobacter will facilitate the ongoing basic research and clinical studies to develop WAP‐8294A into true therapeutics. John Wiley and Sons Inc. 2019-09-14 /pmc/articles/PMC6801147/ /pubmed/31520522 http://dx.doi.org/10.1111/1751-7915.13484 Text en © 2019 The Authors. Microbial Biotechnology published by John Wiley & Sons Ltd and Society for Applied Microbiology. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Chen, Xusheng
Li, Shanren
Yu, Lingjun
Miller, Amanda
Du, Liangcheng
Systematic optimization for production of the anti‐MRSA antibiotics WAP‐8294A in an engineered strain of Lysobacter enzymogenes
title Systematic optimization for production of the anti‐MRSA antibiotics WAP‐8294A in an engineered strain of Lysobacter enzymogenes
title_full Systematic optimization for production of the anti‐MRSA antibiotics WAP‐8294A in an engineered strain of Lysobacter enzymogenes
title_fullStr Systematic optimization for production of the anti‐MRSA antibiotics WAP‐8294A in an engineered strain of Lysobacter enzymogenes
title_full_unstemmed Systematic optimization for production of the anti‐MRSA antibiotics WAP‐8294A in an engineered strain of Lysobacter enzymogenes
title_short Systematic optimization for production of the anti‐MRSA antibiotics WAP‐8294A in an engineered strain of Lysobacter enzymogenes
title_sort systematic optimization for production of the anti‐mrsa antibiotics wap‐8294a in an engineered strain of lysobacter enzymogenes
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801147/
https://www.ncbi.nlm.nih.gov/pubmed/31520522
http://dx.doi.org/10.1111/1751-7915.13484
work_keys_str_mv AT chenxusheng systematicoptimizationforproductionoftheantimrsaantibioticswap8294ainanengineeredstrainoflysobacterenzymogenes
AT lishanren systematicoptimizationforproductionoftheantimrsaantibioticswap8294ainanengineeredstrainoflysobacterenzymogenes
AT yulingjun systematicoptimizationforproductionoftheantimrsaantibioticswap8294ainanengineeredstrainoflysobacterenzymogenes
AT milleramanda systematicoptimizationforproductionoftheantimrsaantibioticswap8294ainanengineeredstrainoflysobacterenzymogenes
AT duliangcheng systematicoptimizationforproductionoftheantimrsaantibioticswap8294ainanengineeredstrainoflysobacterenzymogenes